Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031953 · ClinicalTrials.gov registry record · Phase 1
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01031953 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 34 participants.
The verdict
NCT01031953, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
Interventions
- OTHER survey administration
- PROCEDURE quality-of-life assessment
- DRUG systemic chemotherapy
- DRUG fosaprepitant dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031953
The ClinicalTrials.gov registry entry for NCT01031953 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which survey administration is the first listed.
NCT01031953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01031953 about?
NCT01031953 is a clinical study titled "Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy". RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea ...
What is the current status of trial NCT01031953?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2008-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01031953?
The interventions under investigation include: survey administration (OTHER), quality-of-life assessment (PROCEDURE), systemic chemotherapy (DRUG), fosaprepitant dimeglumine (DRUG).
Who is sponsoring clinical trial NCT01031953?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.